Lee Financial Co Increases Holdings in Merck & Co., Inc. (NYSE:MRK)

Lee Financial Co lifted its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 44.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 14,268 shares of the company’s stock after buying an additional 4,414 shares during the period. Lee Financial Co’s holdings in Merck & Co., Inc. were worth $1,558,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of MRK. Bare Financial Services Inc acquired a new position in Merck & Co., Inc. in the 4th quarter valued at $28,000. Rakuten Securities Inc. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth $30,000. RIA Advisory Group LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $30,000. AlphaMark Advisors LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $34,000. Finally, Valued Wealth Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $42,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Truist Financial raised their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. Barclays raised their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Merck & Co., Inc. in a report on Thursday, April 18th. Berenberg Bank lifted their price objective on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Finally, UBS Group upped their price objective on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.33.

Read Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

MRK traded up $0.31 during trading hours on Friday, hitting $131.19. The company’s stock had a trading volume of 8,281,595 shares, compared to its average volume of 7,287,899. The company has a 50-day simple moving average of $127.27 and a 200 day simple moving average of $118.62. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $332.28 billion, a PE ratio of 145.77, a PEG ratio of 1.67 and a beta of 0.39. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. During the same period last year, the company earned $1.40 earnings per share. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, sell-side analysts expect that Merck & Co., Inc. will post 8.69 EPS for the current year.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.